



Overview/description

Feline vaccine-associated sarcoma: Myth or reality?

Fibrosarcomas are relatively common in cats. It is of utmost importance to differentiate vaccine or injection site-associated sarcoma (VAS) from non-vaccine-associated sarcoma as the prognosis and treatment strategies for each type differ significantly. In this webcast, Dr. Philip J. Bergman will focus on the history, possible impact from adjuvant vs. not, diagnosis, prognosis, and therapy of cats with VAS. Join us as we discuss strategies to help veterinary teams manage this condition effectively.

Speaker's bio and credentials



Philip J. Bergman, DVM, MS, PhD, Dipl. ACVIM (Oncology)

Dr. Philip J. Bergman is the Director of Clinical Studies for Mars Veterinary Health and VCA and serves as the principal veterinary investigator for the fully licensed canine melanoma vaccine, Oncept®. He is also an adjunct faculty member at the Memorial Sloan-Kettering Cancer Center.

Before joining VCA-Antech, Dr. Bergman was the Chief Medical Officer at BrightHeart Veterinary Centers from July 2007 to August 2011, and he led the Donaldson-Atwood Cancer Center at AMC from 1999 to 2007. After finishing veterinary school at Colorado State University (CSU) in 1990, he interned at Kansas State University (1990–1991) and returned to CSU for his medical oncology residency (1991–1994). He then earned a PhD Fellowship in human cancer biology from the M.D. Anderson Cancer Center in Houston (1994–1999). Dr. Bergman has also served as Chair of the ACVIM Board of Regents and President of the Veterinary Cancer Society.



Questionnaire

1. **In the AAEP/VAFSTF Guidelines, where is the recommended vaccination site?**
 - Interscapular SQ
 - Intermuscular lumbar muscles
 - Over each hip SQ
 - Over the limb
 - Below the elbow or stifle

2. **When presented with a cat with a mass that you suspect may be at a vaccination or injection site, you should:**
 - Obtain a fine needle aspirate for cytology
 - Perform an incisional biopsy for histopathology
 - Do a marginal excision of the mass
 - Do a wide resection of the mass
 - Do a radical resection of the mass

3. **Before surgery for VAS/FISS, the staging test that is most useful is:**
 - Chest radiographs
 - CT scan of the thorax
 - CT scan of the thorax and mass
 - MRI of the thorax and mass
 - Blood work and blood typing

4. **The recommended surgical approach for FISS is:**
 - 3 cm radial margins and 1 fascial plane deep
 - 3 cm radial margins and 2 fascial planes deep
 - 5 cm radial margins and 1 fascial plane deep
 - 5 cm radial margins and 2 fascial planes deep
 - Dependant upon the site of the tumour

5. **We can decrease the risk and impact of FISS on our patients and clients by:**
 - Tailoring vaccines to each patient to avoid overvaccination
 - Using nonadjuvanted vaccines when feasible
 - Vaccinating low on the limb
 - Performing incisional biopsy of masses that develop at vaccine sites
 - All of the above



6. Which of the following have been scientifically linked to the development of VAS/FISS?
- Adjuvanted vaccines
 - Long-acting penicillins
 - Injectable corticosteroids
 - Cold vaccine administration
 - All of the above
7. In a comparative study (Srivistav et al., 2012), what was the risk of development of VAS/FISS in cats given an adjuvanted vaccine when the baseline control comparison group was a nonadjuvanted vaccine?
- No difference
 - Two-fold greater risk
 - Two-fold less risk
 - Five-fold greater risk
 - ≥ 10 -fold greater risk
8. What percentage of feline VAS/ISS patients have p53 mutations in their tumour versus in their normal tissue (i.e., germline), respectively?
- 25% and 25%
 - 25% and 0%
 - 60% and 0%
 - 0% and 60%
 - None of the above
9. What percentage of cats with VAS/FISS have distant metastases at presentation and necropsy, respectively?
- 5% and 30%–40%
 - 5% and $\geq 75\%$
 - 30% - 40% and $\geq 75\%$
 - $\geq 75\%$ and $\geq 75\%$
 - None of the above
10. For cats with VAS/FISS, what is the recurrence rate with radical excision as reported by Kuntz et al?
- $\leq 5\%$
 - $\sim 15\%$
 - $\sim 50\%$
 - $\geq 90\%$
 - None of the above



COMMUNIVET™

PERSONAL INFORMATION:

First name:

Last name:

Type:

(Veterinarian, Technician)

Licence number:

Province where you practise:

Email:



COMMUNIVET™

CERTIFICATE OF COMPLETION

Educational webcast

Feline vaccine-associated sarcoma: Myth or reality?

Presented by

Philip J. Bergman, DVM, MS, PhD, Dipl. ACVIM (Oncology)

This document confirms that

Dr. Lorem Ipsum

has viewed the above-mentioned webcast and has answered and submitted the questionnaire meant to evaluate the understanding of the content.

Date:

Province of licensure:

Licence number:

CE credit (s) earned: 2